A carregar...
Second-line therapies in HCC: emergence of resistance to sorafenib
There is a need for second line therapies in patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals of brivanib in phase 2 studies reported herein have yet to be confirmed in phase 3 trials. Identification of the molecular mechanisms driving sorafenib resistan...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3336075/ https://ncbi.nlm.nih.gov/pubmed/22355010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0151 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|